Obermeyer Wealth Partners Decreases Stock Holdings in Zoetis Inc. $ZTS

Obermeyer Wealth Partners decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 62.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 46,863 shares of the company’s stock after selling 78,600 shares during the quarter. Obermeyer Wealth Partners’ holdings in Zoetis were worth $5,896,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Halbert Hargrove Global Advisors LLC raised its position in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the last quarter. Global Wealth Strategies & Associates purchased a new position in Zoetis in the 4th quarter worth about $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis in the 3rd quarter worth about $31,000. Lodestone Wealth Management LLC purchased a new stake in shares of Zoetis during the 4th quarter valued at about $30,000. Finally, Holos Integrated Wealth LLC purchased a new stake in shares of Zoetis during the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ZTS. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. BTIG Research reaffirmed a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus price target of $152.25.

Zoetis Price Performance

NYSE ZTS opened at $116.92 on Friday. Zoetis Inc. has a 52 week low of $113.29 and a 52 week high of $172.23. The firm has a market capitalization of $49.18 billion, a P/E ratio of 19.42, a PEG ratio of 1.77 and a beta of 0.98. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company has a 50-day moving average price of $120.83 and a 200-day moving average price of $125.53.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts anticipate that Zoetis Inc. will post 7.02 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is currently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.